Pentavere Research Group Inc. has been awarded the first Takeda Canada Innovation Challenge. The Innovation Challenge was launched in January 2022 to accelerate partnerships in identifying new digital technologies and artificial intelligence (AI) solutions that support enhanced patient care in inflammatory bowel disease (IBD) or rare disease conditions.
Pentavere Research Group Inc. is a clinical discovery company that has developed a breakthrough, proprietary, artificial intelligence (AI) engine called DARWEN™, which accelerates discovery from vast amounts of clinical text. DARWEN™ unlocks value, insights and evidence from clinical information which is impossible to analyze by human intelligence alone.
Pentavere will have the opportunity to collaborate and benefit from Takeda’s expertise and extensive international network, as well as funding, to build a proof of concept project in the areas of rare diseases.
The Takeda Canada Innovation Challenge received multiple submissions within the fields of early diagnosis or integrated and personalized care, applicable to the therapeutic areas of inflammatory bowel disease (ulcerative colitis or Crohn’s disease) or rare genetic diseases.
Like this:
Like Loading...
Related
This entry was posted on June 21, 2022 at 10:25 am and is filed under Commentary with tags Pentavere, Takeda. You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
Takeda Canada Innovation Challenge Awarded To Pentavere
Pentavere Research Group Inc. has been awarded the first Takeda Canada Innovation Challenge. The Innovation Challenge was launched in January 2022 to accelerate partnerships in identifying new digital technologies and artificial intelligence (AI) solutions that support enhanced patient care in inflammatory bowel disease (IBD) or rare disease conditions.
Pentavere Research Group Inc. is a clinical discovery company that has developed a breakthrough, proprietary, artificial intelligence (AI) engine called DARWEN™, which accelerates discovery from vast amounts of clinical text. DARWEN™ unlocks value, insights and evidence from clinical information which is impossible to analyze by human intelligence alone.
Pentavere will have the opportunity to collaborate and benefit from Takeda’s expertise and extensive international network, as well as funding, to build a proof of concept project in the areas of rare diseases.
The Takeda Canada Innovation Challenge received multiple submissions within the fields of early diagnosis or integrated and personalized care, applicable to the therapeutic areas of inflammatory bowel disease (ulcerative colitis or Crohn’s disease) or rare genetic diseases.
Share this:
Like this:
Related
This entry was posted on June 21, 2022 at 10:25 am and is filed under Commentary with tags Pentavere, Takeda. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.